Markers in breast cancer: Does CEA add to the detection by CA 15.3?
- 1 July 1988
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 11 (3), 273-276
- https://doi.org/10.1007/bf01807287
Abstract
211 patients with various stages of breast cancer were studied by both the CA 15.3 and CEA markers to assess whether the latter may increase the screening sensitivity of the former. While both markers were equally specific, CA 15.3 was seen to be much more sensitive than CEA (p<0.0001). Also, the addition of the CEA did not add appreciably (7%) to positive detection by CA 15.3. There appears to be no advantage to including CEA in a marker panel to follow the course of breast carcinoma.This publication has 10 references indexed in Scilit:
- Value of CA 15:3 in the follow-up of breast cancer patientsBritish Journal of Cancer, 1987
- Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.Journal of Clinical Oncology, 1986
- CA 15.3 - EARLY RESULTS OF A NEW BREAST-CANCER MARKER1986
- Carcinoembryonic antigen in breast cancer. Clinical reviewAmerican Journal Of Medicine, 1986
- Evaluation of CA15/3 serum levels in breast cancer patients.1986
- Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancerCancer, 1984
- Biological markers for breast carcinomaCancer, 1984
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsHybridoma, 1984
- Prognostic significance of CEA in breast cancer: a statistical studyEuropean Journal of Cancer and Clinical Oncology, 1981